在 HDV (LOWR-1) 中使用和不使用利托那韦的 Lonafarnib (LOWR-1)
一项开放标签、剂量范围、概念验证研究,以评估 Lonafarnib 加用和不加利托那韦对慢性感染三角洲肝炎 (HDV) 患者的安全性和有效性 (LOWR-1)
To Evaluate the Safety and Efficacy of Lonafarnib with and without Ritonavir Boosting in Adults With Genotype 1 Chronic Hepatitis D Virus (HDV) Infection (LOWR-1).
研究概览
详细说明
Chronic delta hepatitis is a serious form of chronic liver disease caused by infection with the hepatitis D virus (HDV), a small RNA virus that requires farnesylation of its major structural protein (HDV antigen) for replication. Twenty-one subjects with chronic delta hepatitis will be randomized to receive one of seven different doses of lonafarnib. Dosing will occur over 4-12 weeks, depending on treatment arm, and during that time, evidence of antiviral response will be assessed by frequent measurements of HDV-RNA. The primary therapeutic endpoint will be an improvement in quantitative serum HDV RNA levels after treatment with lonafarnib therapy. The primary safety endpoint will be the ability to tolerate the drug at the prescribed dose for the treatment duration. Several secondary endpoints will be measured, including side effects, ALT levels, and symptoms. Therapy will be stopped for intolerance to lonafarnib. This study is designed as a phase 2a study assessing the safety, tolerance and antiviral activity of seven dose combinations of lonafarnib with and without ritonavir boosting.
研究类型
注册 (实际的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Ankara、土耳其(türkiye)
- Ankara University Medical School
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
-
Males or females, 18 to 65 years of age who are diagnosed with HDV by PCR
-
Chronic hepatitis D infection, genotype 1, documented by a positive anti-HDV Ab test at least of 6 months duration and detectable HDV RNA by PCR within 3 months to study entry
-
Liver biopsy within the last two years
-
Positive viral load by quantitative PCR
-
Electrocardiogram (ECG) shows no acute ischemia or clinically significant abnormality and a QT/QTc interval <450 milliseconds - using Bazett's correction
-
Females of childbearing potential (intact uterus and within 1 year since the last menstrual period) should be non-lactating and have a negative serum pregnancy test. In addition, these subjects should agree to use one of the following acceptable birth control methods throughout the study:
- abstinence
- surgical sterilization (bilateral tubal ligation, hysterectomy, bilateral oophorectomy) six months minimum
- IUD in place for at least six months
- barrier methods (condom or diaphragm) with spermicide
- surgical sterilization of the partner (vasectomy for six months)
- hormonal contraceptives for at least three months prior to the first dose of study drug
-
Willing and able to comply with study procedures and provide written informed consent
Exclusion Criteria:
-
Participation in a clinical trial with or use of any investigational agent within 30 days of Study Visit 1
-
Patients co-infected with HIV
-
Patients with screening tests positive for HCV, or anti-HIV Ab
-
History of decompensated cirrhosis within the past year
-
Active jaundice defined by total bilirubin > 2.0 excluding Gilbert's disease
-
INR ≥ 1.5
-
Eating disorder or alcohol abuse within the past 2 years, excessive alcohol intake (> 20 g per day for females (1.5 standard alcohol drinks) or > 30 g per day for males (2.0 standard alcohol drinks) (a standard drink contains 14 g of alcohol: 12 oz of beer, 5 oz of wine or 1.5 oz of spirits) (1.0 fluid oz (US) = 29.57 mL).
-
Drug abuse within the last six months with the exception of cannabinoids and their derivatives
-
Patients with absolute neutrophil count (ANC) < 1500 cells/mm^3; platelet count < 100,000 cells/mm^3; hemoglobin < 12 g/dL for women and < 13 g/dL for men; abnormal TSH,T4, or T3 or thyroid function not adequately controlled; or serum creatinine concentration ≥ 1.5 times upper limit of normal (ULN)
-
History or clinical evidence of any of the following:
- variceal bleeding, ascites, hepatic encephalopathy, CTP score > 6, decompensated liver disease or any other form of non-viral hepatitis
- immunologically mediated disease (e.g., rheumatoid arthritis, inflammatory bowel disease, severe psoriasis, systemic lupus erythematosus) requiring more than intermittent nonsteroidal anti-inflammatory medications for management or that requires frequent or prolonged use of corticosteroids (inhaled asthma medications are allowed)
- any malignancy within 3 years except for basal cell skin cancer
- significant or unstable cardiac disease (e.g., angina, congestive heart failure, uncontrolled hypertension, history of arrhythmia)
- chronic pulmonary disease (e.g., chronic obstructive pulmonary disease) associated with functional impairment
- severe or uncontrolled psychiatric disease, including severe depression, history of suicidal ideation, suicidal attempts or psychosis requiring medication and/or hospitalization 2
-
Patients with a body mass index > 30 kg/m^2
-
Concomitant drugs known to prolong the QT interval
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:lonafarnib - I
lonafarnib 200 mg BID; n=3 |
antiviral farnesyl transferase inhibitor
其他名称:
|
|
实验性的:lonafarnib - II
lonafarnib 300 mg BID; n=3 |
antiviral farnesyl transferase inhibitor
其他名称:
|
|
实验性的:lonafarnib - III
lonafarnib 100 mg TID; n=3 |
antiviral farnesyl transferase inhibitor
其他名称:
|
|
实验性的:lonafarnib/PEG IFN-a - I
lonafarnib 100 mg BID + PEG IFN-a 180 ug QW; n=3 |
antiviral farnesyl transferase inhibitor
其他名称:
immunomodulator
其他名称:
|
|
实验性的:lonafarnib/PEG IFN-a - II
lonafarnib 200 mg BID + PEG IFN-a 180 ug QW; n=3 |
antiviral farnesyl transferase inhibitor
其他名称:
immunomodulator
其他名称:
|
|
实验性的:lonafarnib/PEG IFN-a - III
lonafarnib 300 mg BID + PEG IFN-a 180 ug QW; n=2 |
antiviral farnesyl transferase inhibitor
其他名称:
immunomodulator
其他名称:
|
|
实验性的:lonafarnib/ritonavir
lonafarnib 100 mg BID + ritonavir 100 mg QD; n=3 |
antiviral farnesyl transferase inhibitor
其他名称:
CYP 3A4 inhibitor, lonafarnib booster
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Improvement in Quantitative Serum HDV RNA Levels After 4-12 Weeks of Lonafarnib-based Therapy
大体时间:4-12 weeks
|
log HDV RNA decline from baseline to end of treatment (4-12 weeks of lonafarnib-based therapy) |
4-12 weeks
|
合作者和调查者
调查人员
- 首席研究员:Cihan Yurdaydin, MD、Ankara University
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- EIG-300
- Application #1128309 (其他标识符:Turkish Regulatory Authority)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.